Pages that link to "Q38841480"
Jump to navigation
Jump to search
The following pages link to Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine? (Q38841480):
Displaying 14 items.
- Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein. (Q30398731) (← links)
- An outbreak of acute respiratory illnesses in primary school children with low vaccine uptake, UK, 2016. (Q40058384) (← links)
- The road to a more effective influenza vaccine: Up to date studies and future prospects (Q40060218) (← links)
- cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue (Q47170879) (← links)
- Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses. (Q47555220) (← links)
- Influenza vaccine response: future perspectives (Q47889238) (← links)
- Neutralizing Anti-Hemagglutinin Monoclonal Antibodies Induced by Gene-Based Transfer Have Prophylactic and Therapeutic Effects on Influenza Virus Infection (Q59358022) (← links)
- Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants (Q59359962) (← links)
- Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies (Q60045509) (← links)
- Influenza Vaccination and Guillain-Barré Syndrome: Reality or Fear (Q89497200) (← links)
- A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(αK): A phase II study (Q91776119) (← links)
- A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study (Q92147393) (← links)
- Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections (Q92404820) (← links)
- Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys (Q104075616) (← links)